Neoadjuvant Plus Adjuvant or Only Adjuvant Nab-Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer: A Prospective, Randomized, Controlled, Phase II Study of the AIO (Working Group for Medical Oncology From the German Cancer Society) Pancreatic Cancer Group
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms NEONAX
- 22 Aug 2019 Planned End Date changed from 1 Sep 2024 to 1 Aug 2022.
- 22 Aug 2019 Planned primary completion date changed from 1 Jul 2021 to 1 Aug 2022.
- 04 Jun 2019 Results (n=48) patients assessing the safety of the protocol in resectable pancreatic cancer patients in peri-operative setting, presented at the 55th Annual Meeting of the American Society of Clinical Oncology